Medpace Shares Rise After 2Q Earnings Beat Estimates

Dow Jones07-24

Shares of Medpace Holdings rose after the clinical contract research organization's second-quarter earnings beat estimates.

The stock was up 15% to $606.08 in recent trading, and rose 8.1% since the start of the year.

Medpace reported net income of $121.4 million, or $4.25 a share, compared with $90.3 million, or $3.10 a share, a year earlier.

Revenue rose 17% to $707.3 million. Analysts polled by FactSet expected $689.5 million.

Operating income was $146.8 million.

Medpace forecast fiscal 2026 revenue between $2.81 billion and $2.89 billion and guided for net income between $494 million and $514 million. Analysts polled by FactSet are expecting fiscal 2026 revenue of $2.77 billion and net income of $493.2 million.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 23, 2026 13:52 ET (17:52 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653727973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653727973","market":"sg","top_or_hot":-1,"title":"Medpace Shares Rise After 2Q Earnings Beat Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Medpace Holdings rose after the clinical contract research organization's second-quarter earnings beat estimates. \n</p>\n<p>\n  The stock was up 15% to $606.08 in recent trading, and rose 8.1% since the start of the year. \n</p>\n<p>\n  Medpace reported net income of $121.4 million, or $4.25 a share, compared with $90.3 million, or $3.10 a share, a year earlier. \n</p>\n<p>\n  Revenue rose 17% to $707.3 million. Analysts polled by FactSet expected $689.5 million. \n</p>\n<p>\n  Operating income was $146.8 million. \n</p>\n<p>\n  Medpace forecast fiscal 2026 revenue between $2.81 billion and $2.89 billion and guided for net income between $494 million and $514 million. Analysts polled by FactSet are expecting fiscal 2026 revenue of $2.77 billion and net income of $493.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 13:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace Shares Rise After 2Q Earnings Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace Shares Rise After 2Q Earnings Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-24 01:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Medpace Holdings rose after the clinical contract research organization's second-quarter earnings beat estimates. \n</p>\n<p>\n  The stock was up 15% to $606.08 in recent trading, and rose 8.1% since the start of the year. \n</p>\n<p>\n  Medpace reported net income of $121.4 million, or $4.25 a share, compared with $90.3 million, or $3.10 a share, a year earlier. \n</p>\n<p>\n  Revenue rose 17% to $707.3 million. Analysts polled by FactSet expected $689.5 million. \n</p>\n<p>\n  Operating income was $146.8 million. \n</p>\n<p>\n  Medpace forecast fiscal 2026 revenue between $2.81 billion and $2.89 billion and guided for net income between $494 million and $514 million. Analysts polled by FactSet are expecting fiscal 2026 revenue of $2.77 billion and net income of $493.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 13:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEDP","symbol_name":"Medpace Holdings Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653727973","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653727973","pubTimestamp":1784829120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Medpace Holdings rose after the clinical contract research organization's second-quarter earnings beat estimates.The stock was up 15% to $606.08 in recent trading, and rose 8.1% since the start of the year.Medpace reported net income of $121.4 million, or $4.25 a share, compared with $90.3 million, or $3.10 a share, a year earlier.Revenue rose 17% to $707.3 million. Analysts polled by FactSet expected $689.5 million.Operating income was $146.8 million.Medpace forecast fiscal 2026 revenue between $2.81 billion and $2.89 billion and guided for net income between $494 million and $514 million. Analysts polled by FactSet are expecting fiscal 2026 revenue of $2.77 billion and net income of $493.2 million.Write to Grace Yoon at grace.yoon@wsj.com Dow Jones NewswiresJuly 23, 2026 13:52 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MEDP":"Medpace Holdings Inc."},"translate_title":"第二季度盈利超出预期后 Medpace 股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":1.5},"content_text":"Shares of Medpace Holdings rose after the clinical contract research organization's second-quarter earnings beat estimates. \n\n\n  The stock was up 15% to $606.08 in recent trading, and rose 8.1% since the start of the year. \n\n\n  Medpace reported net income of $121.4 million, or $4.25 a share, compared with $90.3 million, or $3.10 a share, a year earlier. \n\n\n  Revenue rose 17% to $707.3 million. Analysts polled by FactSet expected $689.5 million. \n\n\n  Operating income was $146.8 million. \n\n\n  Medpace forecast fiscal 2026 revenue between $2.81 billion and $2.89 billion and guided for net income between $494 million and $514 million. Analysts polled by FactSet are expecting fiscal 2026 revenue of $2.77 billion and net income of $493.2 million. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2026 13:52 ET (17:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653727973","isCrawlerRequest":true}